Andrew Rosenbaum, MD
Cardiovascular Disease · Rochester, MNNPI 1336580935
Payments from drug & device makers
Across 80 payments — averaging $518.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$39K
- Kiniksa Pharmaceuticals, Ltd.$2K
- Medtronic$894
- Cvrx, Inc.$146
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
- Impulse Dynamics (USA) Inc.$56
- plus $26 from 1 others
What the payments were for
- Consulting fees$3,12432%
- Travel & lodging$2,55226%
- Food & beverage$4,09242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 63 | $38,553 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $1,675 |
| Medtronic(2 entities) | 10 | $894 |
| Cvrx, Inc. | 1 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Impulse Dynamics (USA) Inc. | 2 | $56 |
| Abiomed | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,450 in reported general payments places this provider in the 70th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 122 | $140,798 |
| JardianceEmpagliflozin | 95 | $137,627 |
| FarxigaDapagliflozin Propanediol | 71 | $73,973 |
| EliquisApixaban | 54 | $65,354 |
| Sirolimus | 33 | $46,617 |
| VerquvoVericiguat | 23 | $18,548 |
| Mycophenolate Mofetil | 55 | $4,574 |
| Clonidine | 18 | $3,299 |
| Amiodarone Hcl | 13 | $2,416 |
| Metoprolol Succinate | 142 | $2,265 |
| Torsemide | 52 | $2,074 |
| Bisoprolol Fumarate | 45 | $1,263 |
| Bumetanide | 16 | $1,239 |
| Rosuvastatin Calcium | 99 | $1,083 |
| Losartan Potassium | 66 | $1,074 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rochester
- Jae OhRochester$7.9M
- Yogesh ReddyRochester$7.9M
- Mayra GuerreroRochester$7.1M
- Martha GroganRochester$6.3M
- Mackram EleidRochester$3.5M
- David HolmesRochester$2.4M
- Mohamad Adnan AlkhouliRochester$2.1M
- Srijoy MahapatraRochester$2M
- Jeffrey GeskeRochester$1.9M
- Charanjit RihalRochester$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.